NCT05528302 · ACTIVE NOT RECRUITING

Technology Assisted Cognitive Behavioural Therapy Intervention for Anxiety in People Living With Cognitive Impairment

This trial is testing whether cognitive behavioural therapy, delivered remotely via a software platform, can help reduce anxiety in people who already have mild cognitive impairment or dementia. Researchers are measuring how well the tech-assisted therapy works compared to a control condition. Phase NA here means this is a practical, real-world style trial rather than a drug-approval study.

You may qualify if

  • Persons aged 18 years or over
  • Persons with a diagnosis of mild cognitive impairment (MCI) or dementia of any aetiology based on a previous diagnosis by a clinician or scoring above threshold (≤32; MCI ≤32 and dementia ≤27) for cognitive impairment in the Modified Telephone Interview for Cognitive Impairment (TICS-M).
  • Screening positive for anxiety (scoring ≥9 on Geriatric Anxiety Inventory, GAI), and/or subjective complaints of anxiety and/ or clinician diagnosis of a current anxiety disorder and screening positive for anxiety using the Rating Anxiety in Dementia scale (scoring ≥11 on RAID)

You're excluded if

  • Persons with severe dementia
  • Persons unable to communicate or complete questionnaires
  • Persons who have a current risk of suicide within the last month as determined by the study clinical expert team.
  • Persons with major depression as the primary complaint without reported symptoms of anxiety
  • Persons with comorbid psychiatric conditions

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2026-02-04

View full record on ClinicalTrials.gov

All APOE4 clinical trials